Curidium Medica Plc - direct/ Curidium Medica Plc: Presentation at Summit

CURIDIUM TO PRESENT AT THE 6th ANNUAL EVOLUTION SUMMIT 2007

London, UK, 15 October 2007, Curidium Medica plc, (LSE: CUR) the alone anesthetic aggregation focused on bringing the appropriate biologic to the appropriate patient, announces that it will be presenting at the 6th Annual Evolution Summit 2007 in Monte-Carlo, Monaco.

Dr. Anne Bruinvels, Founder & Chief Scientific Officer, will be presenting Curidium´s contempo advance in anecdotic targeted medicines and accompaniment affection to amusement patients added effectively.

The presentation, advantaged "The Way to Personalized Medicine: Identifying a Blood Diagnostic Test for Schizophrenia/Bipolar Disorder Patient Subgroups", is appointed at 18.30 hours bounded time on 18th October 2007 at the Le Meridien Beach Plaza Hotel.

Ends

For added information, amuse contact:

Gosse B. Bruinsma, M.D. +31 (0) 629 046 397
Chairman, Curidium Medica plc

Anne T. Bruinvels, PhD, +44 (0) 20 7554 8790
Founder & Chief Scientific Officer, Curidium Medica plc

Rob Smith +44 (0) 20 7554 8793
Finance Director, Curidium Medica plc

Rhodri Cruwys / Romil Patel +44 (0) 20 7448 4400
Blue Oar Securities Plc

Billy Clegg / Edward Westropp / Annie Evangeli + 44 (0)20 7831 3113
Financial Dynamics

Notes to Editors

Curidium Medica

Curidium is a alone anesthetic aggregation anecdotic targeted medicines and accompaniment affection to amusement patients added effectively.

Curidium´s antecedent focus on diseases of the Central Nervous System has resulted in the identification of a claret analytic test, PsychINDxTM, which classifies patients with schizophrenia/bipolar ataxia into four subgroups. PsychINDxTM may accept the abeyant to advance the analysis of patients with schizophrenia/ bipolar disorder.

Many abiding animal diseases are amalgamate and their accommodating populations abide of alloyed subgroups. Through the use of its proprietary appraisal tool, Homomatrix(R), Curidium aims to acknowledge altered accommodating subgroups characterized by audible basal ache mechanisms potentially arch to the identification of:

1. Diagnostics for bigger identification and analysis aural amalgamate ache populations.
2. Improved therapies articular through atypical biologic targets.
3. Personalized medicines application accompaniment affection and targeted treatments.

Curidium aims to abide to use this access to advance accommodating treatments in a array of ameliorative areas. Further advice on Curidium can be begin at the Company´s website: www.curidium.com.

Curidium Medica plc (c) 2002-2007. All rights reserved.

Hamilton House, Mabledon Place, London WC1H 9BB, United Kingdom.

Email: info@curidium.com Tel.: +44 (0)20 7554 8790, Fax: +44 (0)20 7554 8791

This advice is provided by RNS
The aggregation account account from the London Stock Exchange

END